Kestra Advisory Services, LLC Biocryst Pharmaceuticals Inc Transaction History

Kestra Advisory Services, LLC

  • $17.3 Billion
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 09, 2023
SELL
$6.71 - $7.92 $48,983 - $57,816
-7,300 Reduced 27.99%
18,779 $132,000
Q2 2023

Aug 11, 2023
BUY
$6.96 - $8.81 $14,964 - $18,941
2,150 Added 8.98%
26,079 $183,000
Q1 2023

May 12, 2023
BUY
$7.94 - $11.84 $19,016 - $28,356
2,395 Added 11.12%
23,929 $199,000
Q4 2022

Jan 31, 2023
BUY
$10.5 - $14.2 $75,810 - $102,524
7,220 Added 50.44%
21,534 $247,000
Q3 2022

Nov 01, 2022
BUY
$10.79 - $14.81 $154,448 - $211,990
14,314 New
14,314 $180 Million

Others Institutions Holding BCRX

# of Institutions
281
Shares Held
171M
Call Options Held
625K
Put Options Held
739K
View Full List

About BIOCRYST PHARMACEUTICALS INC

BCRX Quotes by TradingView
  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.5B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track Kestra Advisory Services, LLC Portfolio

Follow Kestra Advisory Services, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Kestra Advisory Services, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Kestra Advisory Services, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email